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Disclaimer
The views and opinions expressed in this article are those of the 
authors and do not necessarily reflect the views of the World 
Health Organization. Publication in Gates Open Research does 
not imply endorsement by the Gates Foundation.
Background
Soil-transmitted helminth (STH) infections are caused by 
several species of parasitic worms that are transmitted by eggs 
present in human faeces, which contaminate the soil in areas 
with poor sanitation. STHs cause some of the most common 
infections, with about 1.5 billion people infected worldwide1. 
The three main STHs are roundworm (Ascaris lumbricoides), 
whipworm (Trichuris trichiura) and hookworm (Necator 
americanus and Ancylostoma duodenale). STHs reduce the 
nutritional status of infected individuals1. In particular, infected 
children can be affected by reduced physical fitness and 
impaired growth and cognitive development1. Hookworm 
infection in women of reproductive age (WRA) can lead to 
severe anaemia1. Infections with A. lumbricoides and hookworms 
can be treated effectively with benzimidazole drugs (albenda-
zole, mebendazole). However, benzimidazoles are less effec-
tive against T. trichiura. Dual treatment with albendazole and 
ivermectin increases treatment efficacy for T. trichiura2–4. 
Currently, albendazole and mebendazole are donated to the 
World Health Organization (WHO) for distribution to affected 
populations.
The WHO has announced morbidity control as the main 
public health target for STHs to be achieved by 2030. According 
to the most recent WHO guidelines, morbidity control is 
defined as <2% prevalence of medium-to-high intensity (M&HI) 
infections in preschool-age children (preSAC) and school-age 
children (SAC). WHO treatment guidelines advise preventive 
chemotherapy (PC) by mass drug administration (MDA) to 
achieve morbidity control. Previously, WHO recommended 
school-based PC without including adults. The most recent 
guidelines recommend PC targeted at preSAC, SAC and WRA. 
The frequency of PC is based on the prevalence of STH 
infections in SAC prior to the start of treatment (see decision 
tree in Figure 1 for WHO guidelines up until 2019). The recom-
mended PC coverage is 75% in all targeted populations.
Mathematical models of STH transmission dynamics and 
the impact of interventions have been developed to evaluate 
optimal treatment strategies for achieving the WHO goals. The 
Neglected Tropical Diseases Modelling Consortium (NTDmc) 
funded by the Bill and Melinda Gates Foundation brings 
together research groups from multiple scientific institutions 
working on neglected tropical diseases (NTDs), including STHs. 
Modelling groups based at Erasmus Medical Center (EMC) 
in Rotterdam and Imperial College London (ICL) have led the 
recent work on STHs. A model comparison was carried out 
for the EMC and ICL STH models5. Moreover, joint papers 
evaluating WHO treatment guidelines and monitoring and 
Figure 1. World Health Organization (WHO) decision tree showing the current WHO guidelines to achieve morbidity control in 
school-aged children (SAC) using 75% coverage in SAC (black and orange boxes). The bright red boxes represent the modified guidelines 
assuming 75% community-wide coverage (pre-SAC, SAC, and adults to replace the middle row of boxes that represent the current guidelines. 
This figure has been adapted from Figure 1 in 6 under a CC-BY 4.0 license.
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evaluation strategies have been published6,7. In these predic-
tions it is important to note that models predict true prevalence 
while surveillance data make predictions that are sensitive to the 
diagnostic method employed. The predictions of both models 
are largely comparable, although the EMC model is more 
optimistic about the additional impact of community-wide vs. 
targeted (pre-SAC, SAC and WRA) deworming, which can be 
readily explained by differences in assumptions about how 
rates at which individuals contaminate the environment vary with 
age.
The WHO has proposed new goals for NTDs, including new 
control targets for STHs in the year 2030. Using insights from 
recent modelling work we discuss the feasibility of reaching the 
morbidity target following current guidelines and the risks that 
need to be mitigated to maintain the target (summary in Table 1).
Insights from modelling: Lessons from the past 10 
years for the next 10 years
Our modeling and epidemiological data analyses have shown that 
the current WHO treatment guidelines are sufficient to achieve 
the 2020 morbidity target in settings where the prevalence was 
moderate (20% to 50% in SAC) prior to the start of PC6. For 
higher prevalence settings, community-wide PC and/or targeting 
of WRA will be necessary to achieve the morbidity target6,8 
and/or dual therapy with albendazole and ivermectin for 
T. trichiura6,9. Implementing PC twice-yearly also increases 
chance to achieve the morbidity target for STH6. Scaling down 
or stopping PC as per WHO treatment guidelines is very likely 
to lead to resurgence of infection to levels above the morbidity 
target, unless transmission conditions are addressed with water, 
sanitation and hygiene (WASH)10 or elimination of transmission 
(EOT) is achieved6. If this is not feasible, PC needs to be 
sustained10. Accurate measurements of access and compliance 
to PC remain essential to evaluate and sustain achievement of 
the targets. It is also important to note the poor sensitivity of 
Kato-Katz at low prevalence (models predict true prevalence).
Practical implications of the proposed goals
Measuring the target
Geospatial analyses of recent large-scale epidemiological 
studies of STH prevalence11 show that prevalence heterogeneity is 
considerable within PC implementation units. Our simulations 
suggest that to evaluate PC impact, a sufficient number of villages 
should be sampled in each implementation unit7 for an accurate 
assessment of the prevalence (number of villages depending on 
geospatial variation).
The indicator for the morbidity target will be measured with 
Kato-Katz (or any other validated quantitative technique). 
However, the number of slides/samples used strongly affects the 
measured prevalence12,13. PCR methods, although expensive at 
present, are a much more sensitive diagnostic at low prevalence. 
The indicator threshold would be more meaningful if linked to 
a standardized diagnostic procedure, or to the true prevalence of 
infection from which thresholds for specific diagnostic procedures 
and sampling designs can be derived.
Current egg counting methods suffer from considerable 
measurement error, which is compounded by high variation in 
egg density between and within persons over time13–15, meaning 
that an observed prevalence of M&HI can be well above the 2% 
target by chance. This is further compounded by an increase in 
inter-individual variation in egg counts as infection prevalence 
goes down during PC (likely due to systematic non-access to 
PC). Further, modelling suggests that “prevalence of any infection 
in preSAC and SAC” combined with a higher target threshold is 
a more informative indicator (higher positive predictive value) 
Table 1. Summary of modelling insights and challenges for reaching the WHO 2030 goal for soil-transmitted helminths.
Current WHO Goal (2020) Morbidity control: <1% prevalence of M&HI infections in preSAC and SAC
Proposed new WHO Goal 
(2030)
Morbidity control: <2% prevalence of M&HI infections in preSAC and SAC
Is the new target technically 
feasible under the current 
disease strategy?
Yes, in moderate prevalence settings (20–50% in SAC) in the absence of systematic non-access to 
treatment. For highly endemic settings (prevalence ≥50%), semi-annual PC, including adults or at least 
WRA (hookworm), and/or dual PC (Trichuris) are required. A lot depends on the diagnostic used and 
these targets may have to be revised if the employment of PCR methods reveals much higher levels of 
infection.
Are current tools able to 
reliably measure the target?
Yes, although there is a need to test and identify the optimal design for surveys based on Kato-Katz 
(how many stool samples per person, how many slides per sample) and PCR for the specific purpose 
of evaluating the target and intermediate markers of progress (which are based on prevalence of any 
infection instead of M&HI).
What are the biggest 
unknowns?
Levels of systematic non-access or non-compliance to treatment and its impact on achievement of the 
target; the link between morbidity and present and past cumulated infection intensity and how the current 
parasitological target translates to actual morbidity levels; epidemiological situation in settings with pre-
control prevalences <20% (meaning no implementation of PC) as PC in other areas continues.
What are the biggest risks? Systematic non-access and non-compliance to treatment, low coverage and resurgence after reducing 
treatment frequency, lack of community-wide treatment, especially when hookworm is the dominant 
infection if the intrinsic transmission potential is high.
WHO, World Health Organization; M&HI, medium-to-high intensity; preSAC, preschool-age children; SAC, school-age children; PC, preventative 
chemotherapy; WRA, women of reproductive age; PCR, polymerase chain reaction.
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for meeting the morbidity target and would require a smaller 
sample size because of a higher statistical power7.
Timeline to achieve the target
The 2030 morbidity target will be achievable in some countries. 
The frequency and duration of PC and implied resources 
depend on baseline prevalence and achieved coverage plus 
patterns of individual compliance to treatment6.
Technical feasibility
Treatment guidelines will lead to the achievement of the target 
in some communities, but not in all6. Current WHO guidelines 
do not call for treatment in low prevalence settings (<20%). 
However, these areas may still have a prevalence of M&HI 
>2% in preSAC, SAC and WRA14. In addition, epidemiological 
data from the Tumikia study suggest that with lower prevalence, 
the prevalence of M&HI is relatively higher due to increasing 
aggregation of parasites as MDA coverage rises, likely due to 
a small proportion of persistent non-compliers to treatment. A 
revision of the 20% threshold downwards seems desirable.
WHO guidelines for moderate-prevalence settings suggest 
annual PC of young children, preSAC, SAC and WRA. This 
may be sufficient to reach the morbidity target for settings where 
coverage is sufficiently high (75%) in the absence of systematic 
non-compliance to treatment.
For high-prevalence settings (>50%), WHO guidelines suggest 
semiannual treatment. Here the morbidity target is less likely 
to be achieved following current guidelines, especially for 
hookworm and T. trichiura. As the main burden of hookworm 
infection lies in adults, the morbidity targets will only be 
reached when also treating adults as a whole6, not just WRA8. 
Control of T. trichiura will require community-wide treatment 
with albendazole3 or dual treatment with ivermectin and a 
benzimidazole3,6. If systematic non-access to treatment remains 
high, meeting the target may not be feasible8.
Operational feasibility
Reaching the milestone in 2030 will require community-wide 
coverage and/or targeting of WRA (especially for hookworm), 
with low systematic non-access/non-compliance to PC and little 
coverage heterogeneity within PC implementation units. 
Modelling suggests that the timeline for achieving the target 
is expected to be longer if there is re-importation of disease, 
e.g. by migration for areas with low or no treatment 
coverage16. Meeting the target may require coordination of 
national STH programmes at country borders due to human 
movement.
Ability to sustain achievement of the goal
After stopping or scaling down treatment (which is an option in 
the current WHO guidelines, see Figure 1), infection levels are 
likely to bounce back within one to two years17. Thus, it may 
not be possible to decrease the number of required tablets as 
proposed as a new WHO target6,8. This is further complicated 
by population growth between now and 2030, which could 
necessitate a further increase in the number of treatments 
required for pre-SAC and SAC. See Figure 1 for an alternative 
decision-tree based on recent modelling.
Our analyses suggest that uptake of effective WASH is needed 
to sustain the gains made by PC in the longer term10. If EOT is 
not achieved and PC is stopped or scaled down in the absence 
of effective WASH, the probability of resurgence is very high6. 
In the absence of effective WASH interventions, the sustainability 
of the morbidity targets is undermined by human population 
movement unless PC is continued indefinitely16.
Considerations of cost
Child-targeted treatment for hookworm is cost-effective at 
reducing morbidity in children, even in high-transmission 
settings18,19. Community-wide treatment is predicted to be more 
cost-effective in the longer term with respect to the overall 
morbidity case-years prevented than child-targeted treatment, 
as the main hookworm disease burden lies in adults18,19. Annual 
co-administration of albendazole/mebendazole with ivermectin 
is predicted to be more cost-effective than semi-annual 
albendazole/mebendazole treatment for reducing the prevalence 
of heavy T. trichiura infections in SAC9. In general, achieving 
high coverage and good individual compliance in annual treat-
ment rounds may be more cost-effective than treating twice a 
year with lower coverage.
Risks that need to be mitigated to achieve the stated 
goals
Population movement can re-import infection into a geo-
graphical area that has previously reached morbidity control or 
EOT. Measures to mitigate this risk include aiming for evenly 
high coverage across implementation units and co-ordination of 
programmes across country borders16.
Systematic non-access and non-compliance to treatment in 
repeated rounds of MDA and predisposition to heavy infection 
will create a pool of individuals with high infection burden that 
can re-infect others8,10,20–24. Increasing access as well as coverage 
will be important for achieving the 2030 targets22,23.
Reducing frequency of treatment, as proposed in WHO 
guidelines25 and the new goal for 2030 of reducing the number 
of tablets required for treating STHs, in the absence of EOT 
and/or effective WASH measures can lead to rapid resurgence 
of infection prevalences to pre-treatment levels6,10,26–28. See 
Figure 1 for an alternative decision-tree based on recent 
model-based analyses.
Discussion
The morbidity target is defined in terms of the prevalence of 
M&HI. However, infection intensity does not necessarily reflect 
morbidity accurately, as light infections can be associated 
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with non-negligible morbidity and the severity of symptoms 
associated with M&HI is highly variable29. Furthermore, 
current diagnostic tools have poor sensitivity at low prevalence 
levels. Defining targets depending on the diagnostic used seems 
desirable in future policy formulation.
Transmission dynamic models with parameters estimated from 
cross-sectional and longitudinal epidemiological data show 
that technically EOT is feasible for STH in some settings. It 
is predicted that EOT can be achieved in low-transmission 
settings where A. lumbricoides or T. trichiura are the 
dominant parasites by annual treatment of SAC, assuming 80% 
effective coverage and random compliance at each round of 
treatment30. Where EOT is feasible, it may be more cost- 
effective than continuous morbidity control, provided no 
re-importation occurs19. In high transmission settings, 
community-wide treatment is predicted to be more effective 
(especially for hookworm) and more cost-effective.
Another new WHO goal for 2030 is control of strongyloidia-
sis. This requires ivermectin treatment, which would particularly 
benefit areas with high prevalence of T. trichiura. Currently, 
for policy assessments there is only epidemiological data on 
Strongyloides stercoralis31,32 but no model-based predictions. 
As for the other STH, models will provide useful insights for 
policy formulation.
Future work
Future work that the NTDmc can contribute in support of the 
design and achievement of the WHO 2030 goals will focus 
on: 1) an analysis of the value of different diagnostic methods 
and sampling strategies on M&E of STH morbidity targets and 
predicting the probability of EOT; 2) understanding the role of 
spatial heterogeneity in prevalence and coverage and human 
population movement on STH control programmes; 3) investigat-
ing the risk of emergence of drug resistance as well as whether 
and how monitoring of drug efficacy may help, 4) quantifying 
the link between infection intensity and morbidity; and 
5) assessing the importance of different patterns of individual 
compliance to treatment to achieving the WHO targets as data 
becomes available from large-scale epidemiological studies 
and trials. Other proposed topics for future work include the 
impact of discontinuation of lymphatic filariasis programmes on 
STH, infection models encapsulating molecular epidemiology 
data of who infects whom, defining threshold values for when 
systematic non-access and non-compliance causes failure to 
achieve WHO targets, and development of transmission models 
for Strongyloides stercoralis.
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